News Valerio Therapeutics

Equities

ALVIO

FR0010095596

Real-time Euronext Paris Other stock markets 07:27:39 2024-04-18 am EDT			5-day change	1st Jan Change
0.119 ^EUR	+0.68%		-1.82%	-27.88%

2023	Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	Onxeo SA has Changed its Name to Valerio Therapeutics	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Valerio Therapeutics Société anonyme Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Onxeo : changes its name and becomes Valerio Therapeutics following approval by the Annual General Meeting of June 6, 2023	23-06-06	PU
Onxeo SA has Changed its Name to Valerio Therapeutics	23-06-06	CI
Biophytis' Finance Chief Resigns; Onxeo Exec Named Successor	23-05-02	MT
Onxeo SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Onxeo: Publication of the 2022 Annual Financial Report	23-04-28	BU
Onxeo Reports Full Year 2022 Financial Results and Provides Clinical Development Updates	23-04-24	BU
Onxeo will publish its full-year results on April 24, 2023	23-04-21	BU
Onxeo SA Provides Update on the Development Program For Drug Candidate AsiDNATM	23-01-25	CI
Onxeo : Terms of availability of the preparatory documents for the GM	23-01-18	PU
Half-year liquidity contract statement for ONXEO	23-01-04	BU
Onxeo SA Advances Its Second Lead Candidate Ox425 for the Treatment of Solid Tumors	22-11-30	CI
Onxeo : Inside Information / News release on accounts, results	22-09-13	PU
Onxeo Reports its Half-Year 2022 Financial Results and Provides an Update on its Activities	22-09-13	BU
Onxeo SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-13	CI
High-Grade Glioma Relapse in Children: Onxeo Announces the Enrollment of the First Patient in the Phase 1b/2 Clinical Study Conducted by the European ITCC Consortium and Sponsored by Institut Curie	22-09-01	BU
Onxeo SA Announces the Enrollment of the First Patient in the Phase 1B/2 Clinical Study Conducted by the European Itcc Consortium and Sponsored by Institut Curie	22-09-01	CI
Onxeo Wins Bourse Approval To Delist From Denmark's Nasdaq First North Market	22-08-31	MT
Onxeo Announces That Nasdaq Approved the Delisting of Its Shares From the First North Growth Market in Copenhagen	22-08-30	BU
Onxeo Shareholders OK Delisting From Denmark's Nasdaq First North Market	22-08-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Valerio Therapeutics

Equities

ALVIO

FR0010095596

Summary

Filters